{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:23:03Z","timestamp":1788571383539,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s10620-019-05877-z","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T16:15:35Z","timestamp":1571847335000},"page":"1324-1333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Provider Perceptions of Hepatitis C Treatment Adherence and Initiation"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8184-1546","authenticated-orcid":false,"given":"Grace","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krupa","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshata","family":"Moghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Serper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Calgaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Zickmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obaid","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari","family":"Rogal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,23]]},"reference":[{"key":"5877_CR1","doi-asserted-by":"publisher","first-page":"e186371","DOI":"10.1001\/jamanetworkopen.2018.6371","volume":"1","author":"ES Rosenberg","year":"2018","unstructured":"Rosenberg ES, Rosenthal EM, Hall EW, et al. Prevalence of hepatitis C virus infection in US states and the district of Columbia, 2013 to 2016. JAMA Netw Open. 2018;1:e186371.","journal-title":"JAMA Netw Open"},{"key":"5877_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/hep.20502","volume":"41","author":"JA Dominitz","year":"2005","unstructured":"Dominitz JA, Boyko EJ, Koepsell TD, et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology. 2005;41:88\u201396.","journal-title":"Hepatology"},{"key":"5877_CR3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1177\/1756283X15587481","volume":"8","author":"BP Lam","year":"2015","unstructured":"Lam BP, Jeffers T, Younoszai Z, Fazel Y, Younossi ZM. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Ther Adv Gastroenterol. 2015;8:298\u2013312.","journal-title":"Ther Adv Gastroenterol"},{"key":"5877_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2893.2005.00681.x","volume":"13","author":"S Chainuvati","year":"2006","unstructured":"Chainuvati S, Khalid SK, Kancir S, et al. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and\/or substance use disorders. J Viral Hepat. 2006;13:235\u2013241.","journal-title":"J Viral Hepat"},{"key":"5877_CR5","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599\u20132607.","journal-title":"N Engl J Med"},{"key":"5877_CR6","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","volume":"370","author":"F Poordad","year":"2014","unstructured":"Poordad F, Hezode C, Trinh R, et al. ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973\u20131982.","journal-title":"N Engl J Med"},{"key":"5877_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211\u2013221.","journal-title":"N Engl J Med"},{"key":"5877_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M15-0785","volume":"163","author":"S Zeuzem","year":"2015","unstructured":"Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir\u2013elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1\u201313.","journal-title":"Ann Intern Med"},{"key":"5877_CR9","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483\u20131493.","journal-title":"N Engl J Med"},{"key":"5877_CR10","unstructured":"Sustained virologic response in veterans in VHA care starting DAA therapy in 2014 or later for the Nation. Accessed January 6, 2019."},{"key":"5877_CR11","unstructured":"World Health Organization. Combating hepatitis B and C to reach elimination by 2030: advocacy brief. 2016; \nhttp:\/\/www.who.int\/iris\/handle\/10665\/206453\n\n. Accessed March 14, 2019."},{"issue":"3","key":"5877_CR12","doi-asserted-by":"publisher","first-page":"ofz055","DOI":"10.1093\/ofid\/ofz055","volume":"6","author":"C Rossi","year":"2019","unstructured":"Rossi C, Young J, Martel-Laferriere V, et al. Direct-acting antiviral treatment failure among hepatitis C and HIV-coinfected patients in clinical care. Open Forum Infect Dis. 2019;6(3):ofz055.","journal-title":"Open Forum Infect Dis"},{"key":"5877_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1517\/14656566.2012.653341","volume":"13","author":"V Soriano","year":"2012","unstructured":"Soriano V, Vispo E, Poveda E, Labarga P, Barreiro P. Treatment failure with new hepatitis C drugs. Expert Opin Pharmacother. 2012;13:313\u2013323.","journal-title":"Expert Opin Pharmacother"},{"key":"5877_CR14","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1080\/14656566.2016.1182156","volume":"17","author":"L Benitez-Gutierrez","year":"2016","unstructured":"Benitez-Gutierrez L, Barreiro P, Labarga P, et al. Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opin Pharmacother. 2016;17:1215\u20131223.","journal-title":"Expert Opin Pharmacother"},{"key":"5877_CR15","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3350\/cmh.2016.0107","volume":"22","author":"M Buti","year":"2016","unstructured":"Buti M, Esteban R. Management of direct antiviral agent failures. Clin Mol Hepatol. 2016;22:432\u2013438.","journal-title":"Clin Mol Hepatol"},{"key":"5877_CR16","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s10620-017-4608-9","volume":"62","author":"SS Rogal","year":"2017","unstructured":"Rogal SS, McCarthy R, Reid A, et al. Primary care and hepatology provider-perceived barriers to and facilitators of hepatitis C treatment candidacy and adherence. Dig Dis Sci. 2017;62:1933\u20131943. \nhttps:\/\/doi.org\/10.1007\/s10620-017-4608-9\n\n.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"5877_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/09540120050042891","volume":"12","author":"MA Chesney","year":"2000","unstructured":"Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12(3):255\u2013266.","journal-title":"AIDS Care"},{"key":"5877_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u2013381.","journal-title":"J Biomed Inform"},{"key":"5877_CR19","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1097\/j.pain.0000000000000145","volume":"156","author":"RE Palmer","year":"2015","unstructured":"Palmer RE, Carrell DS, Cronkite D, et al. The prevalence of problem opioid use in patients receiving chronic opioid therapy: computer-assisted review of electronic health record clinical notes. Pain. 2015;156:1208\u20131214.","journal-title":"Pain"},{"key":"5877_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/add.13197","volume":"111","author":"J Grebely","year":"2016","unstructured":"Grebely J, Alavi M, Micallef M, et al. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Addiction. 2016;111:311\u2013319.","journal-title":"Addiction"},{"key":"5877_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","volume":"3","author":"J Grebely","year":"2018","unstructured":"Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018;3:153\u2013161.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5877_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.drugpo.2017.05.032","volume":"47","author":"P Read","year":"2017","unstructured":"Read P, Lothian R, Chronister K, et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Int J Drug Policy. 2017;47:209\u2013215.","journal-title":"Int J Drug Policy"},{"key":"5877_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","volume":"108","author":"JE Zibbell","year":"2018","unstructured":"Zibbell JE, Asher AK, Patel RC, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108:175\u2013181.","journal-title":"Am J Public Health"},{"key":"5877_CR24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.clinthera.2016.11.019","volume":"39","author":"J Taylor","year":"2017","unstructured":"Taylor J, Carr-Lopez S, Robinson A, et al. Determinants of treatment eligibility in veterans with hepatitis C viral infection. Clin Ther. 2017;39:130\u2013137.","journal-title":"Clin Ther"},{"key":"5877_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.drugalcdep.2016.10.021","volume":"169","author":"JI Tsui","year":"2016","unstructured":"Tsui JI, Williams EC, Green PK, Berry K, Su F, Ioannou GN. Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug Alcohol Depend. 2016;169:101\u2013109.","journal-title":"Drug Alcohol Depend"},{"key":"5877_CR26","doi-asserted-by":"publisher","first-page":"e0148596","DOI":"10.1371\/journal.pone.0148596","volume":"11","author":"SS Rogal","year":"2016","unstructured":"Rogal SS, Arnold RM, Chapko M, et al. The patient-provider relationship is associated with hepatitis C treatment eligibility: a prospective mixed-methods cohort study. PLoS ONE. 2016;11:e0148596.","journal-title":"PLoS ONE"},{"key":"5877_CR27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/cid\/cix295","volume":"65","author":"AJ Noska","year":"2017","unstructured":"Noska AJ, Belperio PS, Loomis TP, O\u2019Toole TP, Backus LI. Prevalence of human immunodeficiency virus, hepatitis C virus, and hepatitis B virus among homeless and nonhomeless United States veterans. Clin Infect Dis. 2017;65:252\u2013258.","journal-title":"Clin Infect Dis"},{"key":"5877_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1093\/epirev\/mxu002","volume":"37","author":"LA Beste","year":"2015","unstructured":"Beste LA, Ioannou GN. Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs. Epidemiol Rev.. 2015;37:131\u2013143.","journal-title":"Epidemiol Rev."},{"issue":"8","key":"5877_CR29","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1111\/j.1572-0241.2005.41860.x","volume":"100","author":"EJ Bini","year":"2005","unstructured":"Bini EJ, Brau N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol. 2005;100(8):1772\u20131779.","journal-title":"Am J Gastroenterol"},{"key":"5877_CR30","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1023\/A:1022865515735","volume":"48","author":"G Mishra","year":"2003","unstructured":"Mishra G, Sninsky C, Roswell R, Fitzwilliam S, Hyams KC. Risk factors for hepatitis C virus infection among patients receiving health care in a Department of Veterans Affairs hospital. Dig Dis Sci. 2003;48:815\u2013820. \nhttps:\/\/doi.org\/10.1023\/A:1022865515735\n\n.","journal-title":"Dig Dis Sci"},{"key":"5877_CR31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/0033354916689610","volume":"132","author":"AJ Noska","year":"2017","unstructured":"Noska AJ, Belperio PS, Loomis TP, O\u2019Toole TP, Backus LI. Engagement in the hepatitis C care cascade among homeless veterans, 2015. Public Health Rep. 2017;132:136\u2013139.","journal-title":"Public Health Rep"},{"key":"5877_CR32","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1186\/s12889-016-3671-z","volume":"16","author":"ZC Rich","year":"2016","unstructured":"Rich ZC, Chu C, Mao J, et al. Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals. BMC Public Health. 2016;16:994.","journal-title":"BMC Public Health"},{"key":"5877_CR33","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1001\/jamainternmed.2017.8336","volume":"178","author":"KH Chaiyachati","year":"2018","unstructured":"Chaiyachati KH, Hubbard RA, Yeager A, et al. Association of rideshare-based transportation services and missed primary care appointments: a clinical trial. JAMA Intern Med. 2018;178:383\u2013389.","journal-title":"JAMA Intern Med"},{"key":"5877_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12874-015-0016-z","volume":"15","author":"CT Cunningham","year":"2015","unstructured":"Cunningham CT, Quan H, Hemmelgarn B, et al. Exploring physician specialist response rates to web-based surveys. BMC Med Res Methodol. 2015;15:32.","journal-title":"BMC Med Res Methodol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-05877-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-019-05877-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-05877-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T23:36:40Z","timestamp":1603323400000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-019-05877-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,23]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["5877"],"URL":"https:\/\/doi.org\/10.1007\/s10620-019-05877-z","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,23]]},"assertion":[{"value":"29 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}